Register
Login:
Share:
Email Facebook Twitter

RNS VIDEO: Reabold Resources #RBD raise £6 million and take stake in Danube Petroleum Watch here

EXCLUSIVE: HemoGenyx are creating blood cancer treatments with US$9 billion market potential


Int.biotech. Share Price (IBT)



Share Price Information for Int.biotech. (IBT)


Share Price: 612.00Bid: 609.50Ask: 614.50Change: 0.00 (0.00%)No Movement on Int.biotech.
Spread: 5.00Spread as %: 0.82%Open: 612.00High: 612.00Low: 612.00Yesterday’s Close: 612.00

International Biotechnology Trust Plc Ord 25P

Int.biotech. is listed in the FTSE All-Share, FTSE Small Cap
Int.biotech. is part of the Investment Companies sector






Share Price SpacerPrice
612.00

Share Price SpacerBid
609.50

Share Price SpacerAsk
614.50

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
17,512

Share Price SpacerOpen
612.00

Share Price SpacerHigh
612.00

Share Price SpacerLow
612.00

Share Price SpacerClose
612.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 37.55m £229.79m 750

52 Week High 650.00 52 Week High Date 9-OCT-2017
52 Week Low 539.75 52 Week Low Date 20-DEC-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
16 3,022 3,914 5.147 0.00 23.00 3.76


London South East Users info for Int.biotech.




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

13-Dec-17
15:04:43
613.50
20,000
Buy* 
604.50
614.50
122.70k
Trade Type:
Ordinary
Delayed publication
Historical

15-Dec-17
16:35:23
614.50
627
Buy* 
604.50
614.50
3,853
UT 
Trade Type:
Uncrossing Trade

15-Dec-17
16:29:30
614.50
29
Buy* 
604.50
614.50
178.21
Trade Type:
Automatic execution




View more Int.biotech. trades >>

Directors Deals for Int.biotech. (IBT)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Feb-16Buy
Trade Notifier Information for International Biotech Trust
Jim Horsburgh held the position of Non-Executive Director at International Biotech Trust at the time of this trade.
 Jim Horsburgh
421.71GBX5,00015000
25-Jan-16Buy
Trade Notifier Information for International Biotech Trust
Caroline Gulliver held the position of Non-Executive Director at International Biotech Trust at the time of this trade.
 Caroline Gulliver
468GBX2,5005000
26-Aug-15Buy
Trade Notifier Information for International Biotech Trust
Veronique Bouchet held the position of Non-Executive Director at International Biotech Trust at the time of this trade.
 Veronique Bouchet
493.5GBX2,5007500
View more Int.biotech. directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
1 Nov '17Sheepy57No subject605.00No Opinion
I'm out. Don't see it going up as fast as I expected so it's time to say goodbye. Will try somewhere else.
2 Oct '17Sheepy57GILD got its mojo back618.00No Opinion
Don't give up on GILD stock yet -- go long for free
By Nicolas Chahine, InvestorPlace Contributor | Sep 29, 2017, 9:59 am EDT
Gilead Sciences, Inc. (NASDAQ:GILD) stock suffered a nasty 50% correction from its $123 per share high. It finally found footing in June of this year. The slide started mid 2015 and the stock set a lower high and the lower low until it was finally able to stabilize around $64.00 per share. And therein lies my opportunity.

GILD Stock: Gilead Sciences, Inc. (GILD)… Read More
7 Sep '17Sheepy57Biotechnology bonanza627.75No Opinion
19 Jul '17Sheepy57Vertex report621.00No Opinion
Vertex Pharmaceuticals Inc. on Tuesday released clinical findings showing its new approach to combating cystic fibrosis substantially improved lung function in patients, lifting hopes for a treatment that could be used by about 68,000 people worldwide — including 24,000 who don’t respond to any existing medicines.

The results prompted Boston-based Vertex to say it plans to launch one or two late-stage clinical trials of the biotech’s three-drug combination in the first half… Read More
13 Jul '17Sheepy57Biotech Q217: it's mostly all gravy606.00No Opinion
http://www.barrons.com/articles/biotech-2q17-its-mostly-all-gravy-1499953599
"SunTrust Robinson Humphrey's biotechnology team expects Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Celgene (CELG), Clovis Oncology (CLVS), Incyte (INCY), Sarepta Pharmaceutical (SRPT), and Tesaro (TSRO) to beat consensus revenue estimates. Regeneron (REGN) and Seattle Genetics (SGEN), on the other hand, "are likely to report in-line results."
Another rosy prediction for the… Read More
29 Mar '17Sheepy57Vertex Pharmaceuticals594.25No Opinion
Vertex Pharmaceuticals shares soared on Wednesday after the company announced two positive phase 3 trial results for a cystic fibrosis combination treatment.

Vertex said it plans to file for U.S. and European approval for the combination of tezacaftor and ivacaftor in the third quarter of 2017, with decisions likely in the first half of 2018.

Cystic fibrosis is a genetic disease that affects more than 30,000 people in the U.S., according to the Cystic Fibrosis Foundation. Symptoms vary by… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Int.biotech. (IBT) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.